Drug Type Colony-stimulating factors |
Synonyms Neulapeg, Pegteograstim (INN), MG-1107 + [1] |
Target |
Action agonists |
Mechanism CSF-3R agonists(Colony stimulating factor 3 receptor agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization |
Drug Highest PhaseApproved |
First Approval Date South Korea (14 Aug 2014), |
Regulation- |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Neutropenia | South Korea | 14 Aug 2014 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Chemotherapy-Induced Febrile Neutropenia | Phase 2 | United States | 04 Oct 2016 | |
Solid tumor | Phase 2 | United States | 04 Oct 2016 |
Phase 2 | Sinonasal Squamous Cell Carcinoma Neoadjuvant | 27 | qrkmvpnnfh(ovfcmaytqf) = aqrgxaavxn xlqbblqmvx (onatiyjuko ) View more | Positive | 24 May 2024 | ||
Phase 2 | Pancreatic carcinoma non-resectable First line | - | peg-GCSF primary prophylaxis | quxhoyyhat(kcotfzhfak) = bxlgfvjeny jnzcdsmdpj (qorayksjmx ) View more | Positive | 24 May 2024 | |
Phase 2 | 32 | ivyuhxvrmq(zspiudildv) = oaczfzmyyf ofqfogqrvf (prbynslzju ) | Negative | 19 May 2021 | |||
filgrastim | ivyuhxvrmq(zspiudildv) = uesupbafsf ofqfogqrvf (prbynslzju ) |